Aspirin for primary prevention of colorectal cancer

Citation

(2008), "Aspirin for primary prevention of colorectal cancer", Clinical Governance: An International Journal, Vol. 13 No. 1. https://doi.org/10.1108/cgij.2008.24813aae.011

Aspirin for primary prevention of colorectal cancer

Aspirin for primary prevention of colorectal cancerC. Dube, A. Rostom, G. Lewin, A. Tsertsvadze, N. Barrowman, C. Code, M. Sampson and D. MoherAnnals of Internal Medicine2007Vol. 146pp. 365-75

This review evaluated the use of aspirin for primary prevention of colorectal cancer. The authors’ concluded that aspirin reduces the incidence of colonic adenoma and colorectal cancer, particularly if used in high doses for more than ten years. The authors stated that aspirin chemoprevention must be weighed against the relatively large costs associated with its adverse effects, as well as the relative inefficacy of aspirin compared with colonoscopy screening in average-risk populations and in the context of regular endoscopic screening for colorectal cancer. The conclusions were primarily based on lower evidence level studies: randomised controlled trials failed to support the findings regarding CRC incidence and mortality, or for adenoma in average-risk populations. The review was well conducted.